Clinical trial
Assessment of Early Detection and Prognosis Based on cfDNA Methylation in Myeloma: a Proof of Concept Study
NCT05693012 is registered in ClinicalTrials.gov with Qiu Lugui as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Assessment of Early Detection and Prognosis Based on cfDNA Methylation in Myeloma: a Proof of Concept Study
- Lead sponsor
- Qiu Lugui
- Phase
- Observational
- Overall status
- Unknown status
- Start date
- August 1, 2022
- Completion date
- December 31, 2024
- Enrollment
- 398 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.